IT - EN
Partnering

PartneringOur Capabilities

Why Recordati as a Partner

Recordati was founded in 1926 in Italy and is today a well-established International specialty pharmaceutical group that thanks to its own R&D activities, to partnerships and acquisitions has grown into an International mid-sized player with a strong and growing interest in rare diseases and speciality care.
We have:
 
  • Commercial presence in Northern, Western, Southern and Eastern Europe:
  1. affiliates in Northern Europe (Nordic countries), Western Europe (Italy, France, Germany, Benelux, Greece, Portugal, Spain, United Kingdom & Ireland), and Central Eastern Europe (Poland, the Czech Republic, Slovakia, Romania) as well as Russia and the other CIS countries, plus Turkey and Tunisia thus serving about 80% of the EU market;
  2. a strong team of well experienced sales & marketing professionals.
  • Recordati Rare Diseases is the group’s wholly owned subsidiary dedicated to the development and sale of drugs for the treatment of rare diseases. These comprise a dedicated pan-European organization complemented by a commercial presence in the Middle East, in Japan, an organization in the USA, Canada, and commercial presence in various other countries (Australia, Mexico, Brazil, Columbia). Genuinely Recordati’s rare diseases business is today a global one.
  • Proven R&D experience in developing drugs treating cardiovascular, urology and metabolic diseases. Examples include both original drugs (lercanidipine, fenticonazole, flavoxate) as well as the commercial development in-licensed products (cariprazine, silodosin, pitavastatin, vitaros and fortacin, juxtapid).
  • Proven capabilities in the management of regulatory procedures and clinical trials in the EU, MENA and the USA.
  • Extensive know-how and full industrial resources covering the manufacturing chain, from active ingredient to finished product (facilities in Italy, France, Ireland, Spain, Czech Republic, Turkey and Tunisia).
  • Financially sound to support R&D investments.
  • Long-standing track record and commitment to partnering.